Boryung’s new antihypertensive agent gets NET certification

Published: 2011-07-01 06:56:00

Updated: 2011-07-01 06:56:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said recently that its novel antihypertensive drug “Kanarb (fimasartan)” has received the domestic New Excellent Technology (NET) certificate from the Ministry of Health and Welfare.

Kanarb, one of angiotensin II receptor antagonists, is the first Korean drug to receive the domestic NET certificate. The certificatio...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.